Year All20252024202320222021202020192018201720162015201420122011 Oct 18, 2023 Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023 Oct 17, 2023 Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital Oct 17, 2023 FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor Oct 13, 2023 Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA Oct 4, 2023 Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023 Sep 28, 2023 Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility Sep 25, 2023 Tenapanor for Hyperphosphatemia Approved in Japan Sep 11, 2023 Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023 Sep 8, 2023 Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference Sep 7, 2023 Ardelyx, Inc. Reports Employment Inducement Grants